Pure Global
NCT06380205

A Study to Evaluate the Drug Interaction Between Povorcitinib and the Oral Contraceptive Levonorgestrel/Ethinyl Estradiol in Healthy Adult Females

A Phase 1, Open-Label Study to Evaluate the Drug Interaction Between Povorcitinib and the Oral Contraceptive Levonorgestrel/Ethinyl Estradiol in Healthy Adult Females
Incyte Corporation·Phase 1·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Healthy Participants
Drug/Device/Intervention
Povorcitinib
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Incyte Corporation
Location
Tempe, United States of America
Timeline & enrollment
Phase
Phase 1
Start date
May 07, 2024
End date
Jun 07, 2024
Enrollment
24 participants
Primary outcome

Levonorgestrel (LNG) concentration in plasma,Ethinyl estradiol (EE) concentration in plasma

Summary

The purpose of this study is to evaluate the drug interaction between povorcitinib and the
 oral contraceptive levonorgestrel/ethinyl estradiol in healthy adult females.

ICD-10 classifications
Seeking and accepting physical, nutritional and chemical interventions known to be hazardous and harmfulHealthy person accompanying sick personRoutine general health check-up of sports teamsObesityPersons with potential health hazards related to communicable diseases
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06380205
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06380205 through Pure Global AI's free database. This Phase 1 trial is sponsored by Incyte Corporation and is currently Recruiting. The study focuses on Healthy Participants. Target enrollment is 24 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.